Vidarabine phosphate is an adenosine monophosphate analogue in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of Vidarabine with antiviral and possibly antineoplastic properties.Vidarabine (Ara-A) is an approved antiviral drug that interfers with the synthesis of viral DNA, and is used to treat herpes simplex and varicella zoster viruses. Vidarabine and Acyclovir have a synergistic effect on wild type . Vidarabine is capable of inhibiting acyclovir-resistant/TK-deficient mutants of HSV and VZV, because it is phosphorylated to its active vidarabine–triphosphate form by cellular kinases and is not dependent for its activation on the viral TK.
Physicochemical Properties
| Molecular Formula | C10H14N5O7P |
| Molecular Weight | 347.22126 |
| Exact Mass | 347.063 |
| Elemental Analysis | C, 34.59; H, 4.06; N, 20.17; O, 32.25; P, 8.92 |
| CAS # | 29984-33-6 |
| Related CAS # | Vidarabine;5536-17-4 |
| PubChem CID | 34768 |
| Appearance | White to off-white solid powder |
| Density | 2.3±0.1 g/cm3 |
| Boiling Point | 798.5±70.0 °C at 760 mmHg |
| Melting Point | 213ºC |
| Flash Point | 436.7±35.7 °C |
| Vapour Pressure | 0.0±3.0 mmHg at 25°C |
| Index of Refraction | 1.905 |
| LogP | -0.22 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 23 |
| Complexity | 481 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | C([C@@H]1[C@H]([C@@H]([C@H](N2C=NC3=C(N)N=CN=C32)O1)O)O)OP(=O)(O)O |
| InChi Key | UDMBCSSLTHHNCD-UHTZMRCNSA-N |
| InChi Code | InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7+,10-/m1/s1 |
| Chemical Name | 9H-Purin-6-amine, 9-(5-O-phosphono-beta-D-arabinofuranosyl)- |
| Synonyms | Vidarabine phosphate; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Antiviral Res.2006 Nov;72(2):157-61 [2]. Antivir Chem Chemother.2004 Sep;15(5):281-5. [3]. Toxicol Appl Pharmacol. 1982 Oct;66(1):143-52. [4].JAMA. 1982 Apr 23;247(16):2261-5. [5]. J Clin Pathol. 1999 Feb;52(2):89-94. |
| Additional Infomation |
Vidarabine Phosphate is a phosphate salt form of vidarabine, a nucleoside analog with activity against herpes simplex virus and varicella zoster virus. Vidarabine is converted to a monophosphate by viral thymidine kinase and is further modified to a triphosphate form by host enzymes. Vidarabine triphosphate directly inhibits DNA polymerase and also acts as a chain terminator in DNA replication. An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties. |
Solubility Data
| Solubility (In Vitro) |
DMSO : 16.67 ~53 mg/mL ( 48.01~198.32 mM ) Water : 3~4.9 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 1.67 mg/mL (4.81 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8800 mL | 14.4001 mL | 28.8002 mL | |
| 5 mM | 0.5760 mL | 2.8800 mL | 5.7600 mL | |
| 10 mM | 0.2880 mL | 1.4400 mL | 2.8800 mL |